Interstitial lung disease associated with amrubicin chemotherapy in patients with lung cancer: a single institutional study

Conclusion Interstitial lung disease occurred in 3.3% of the patients in our study; this appeared to be less frequent than the rates in previous reports. Preexisting pulmonary fibrosis may be a risk factor for interstitial lung disease; however, no fatal cases were found among the patients with asymptomatic pulmonary fibrosis without honeycomb lung. It is thus considered to be necessary to carefully assess the possibility of preexisting pulmonary fibrosis and clarify the presence or absence of honeycomb lung before starting amrubicin chemotherapy.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Original article Source Type: research